Statin Discontinuation Appears Feasible for Many Older Adults Without Prior Cardiovascular Disease
For older adults taking statins to prevent a first heart attack or stroke, the study offers a rare glimpse of what happens when therapy is stopped rather than continued. In nearly 1,900 adults age 70 and older, discontinuing statins produced similar rates of heart attack, stroke and death over two years when compared with ongoing treatment. The finding matters because this is a population in which treatment inertia often persists long after the original risk-benefit calculation was made.
The cohort was not a healthy volunteer sample. Participants had at least two chronic conditions, including histories such as cancer or pulmonary disease, but no prior cardiovascular disease. Their average age was 77, and the study included 53% men and 47% women. In practical terms, these were older adults for whom pill burden, polypharmacy and day-to-day treatment fatigue can become clinically important, even when a medication has been used for years.
Two-Year Outcomes Held Steady After Statin Cessation
Investigators assigned 938 participants to discontinue statins and 942 to continue them, then followed them for heart attack, acute ischemic stroke and all-cause death. At about two years, the discontinuation strategy remained safe by the study’s primary clinical yardstick: there was no significant rise in cardiovascular events or death. The absence of a difference also extended to quality of life, muscle pain, falls and sarcopenia, outcomes that often drive real-world decisions in older patients.
One way to interpret the result is through the biology of primary prevention. Statins lower LDL-C, reduce atherosclerotic plaque progression and blunt the long-term accumulation of vascular risk. In older adults who have never had a cardiovascular event, the absolute benefit may narrow if competing causes of illness and death become more prominent. For many patients, the annual gain from continued lipid lowering may therefore become modest enough that stopping therapy does not trigger an immediate clinical penalty.
The Four-Year Signal Changed the Conversation
The picture became less uniform over longer follow-up. Across as long as four years, 12.7% of participants who discontinued statins experienced heart attack, stroke or death, compared with 9.2% among those who stayed on treatment. The study also described an excess of cardiovascular events among discontinuers over time, amounting to roughly one additional event for every 40 people who stopped statins over two years.
This late divergence is the part clinicians will likely focus on. It suggests that the apparent safety of stopping statins may depend on the time horizon under discussion. A short interval can look reassuring, while longer observation allows atherosclerotic risk to reassert itself. The difference is especially relevant for older adults who are otherwise stable and may feel well enough to question the need for a preventive drug that does not produce immediate subjective benefit.
The result does not support an automatic stop order, but it does support a more individualized approach. For some patients, especially those with limited life expectancy, high treatment burden or low tolerance for medication, discontinuation may be reasonable. For others with a longer expected lifespan and persistent vascular risk, continuing therapy may still offer protection that accrues gradually rather than instantly.
No Clear Tradeoff in Muscle Symptoms or Falls
The trial did not show a quality-of-life advantage for stopping statins, and it did not detect differences in muscle pain, falls or sarcopenia. That matters because those concerns often drive statin discontinuation in routine practice. Many older patients worry that statins are weakening them, slowing them down or contributing to instability, yet this study did not show measurable improvement in those domains after stopping treatment.
The crossover rate complicates the picture but does not erase it. About 14% of participants switched groups during the study, with some discontinuation-arm participants restarting statins and some continuation-arm participants stopping. Additional analyses designed to account for that movement did not materially alter the findings. Even so, crossover softens the separation between treatment arms and makes the longer-term signal more cautious to interpret.
Shared Decision-Making Has to Anchor the Prescription Review
This study is most useful at the bedside, where statin continuation in older age is often treated as a default rather than a decision. The data support a conversation about goals of care, competing comorbidities, life expectancy and patient preference. For an 80-year-old with no prior cardiovascular event who is taking multiple medications, a supervised trial off statins may be reasonable. For another patient of the same age who is robust, active and deeply risk-averse about stroke or myocardial infarction, ongoing treatment may still be the better fit.
The study also reinforces a more nuanced reading of primary prevention. LDL-C remains biologically relevant in later life, but the strength of the treatment imperative may weaken when absolute event rates are lower and medication burden is higher. In that setting, preventive cardiology becomes less about reflexively maintaining every drug and more about selecting the regimen that best matches a patient’s actual risk, not just their age.
The trial ran from November 2021 through April 2026 at 24 clinical centers in Switzerland, France and the Netherlands, and its results were presented as late-breaking science at the American Heart Association’s Scientific Sessions 2026. The full manuscript appeared simultaneously in The New England Journal of Medicine. Even with publication, the central unanswered issue remains practical: which older adults can safely stop statins for years, and which should continue because their residual vascular risk is still high enough to justify ongoing therapy.